Displaying 1–25 of 207 results for Paul Thomas, Managing Editor
Readers recognize tools that break new ground but promise to improve efficiency
Michael Donlon and Dermot Doran of Pfizer Newbridge discuss the challenges and success of the sites YOU Have the Power project.
A talk with sustainability manager Johanna Jobin about the company's new product recycling initiative.
Drug industry environmental stewardship projects are becoming more sophisticated and challenging. Here are examples from AstraZeneca, Bayer, DSM, Pfizer, and EMD Millipore
A joint collaboration claims it has a disruptive technology that can be shipped anywhere, and used in any way. Does it raise the bar for future flexible facilities?
The company aims to leverage the expertise it has always had in-house, yet hadnt fully capitalized on with the pharma industry, says VP Christophe Couturier.
As conventional ways of making drugs give way, we will seek out these people and value their brilliance.
BioNetworks Doug Drabble says there are jobs throughout the state, though workers won't always relocate to take them.
A look at whats new for the cleanroom set.
New research indicates that biopharma manufacturers have a desire for operational excellence but are not using sophisticated methods that are commonplace in other industries.
West and Vetter look to meet the needs of parenteral manufacturers demanding new, safer syringe options.
It is worth having dreams, and worth fulfilling them, says former Novartis employee Anna Kroczak.
Our eighth annual Job Satisfaction and Salary Survey says the big picture is brighter, though not clearer.
Pharmaceutical machine vision technologies are getting simpler and cheaper, and yet tackling more varied applications.
When it comes to patient safety, says Brian Johnson, there should be no competitive advantage.
"OUS" companies are enjoying the U.S. market, and creating a few jobs along the way.
Modularly constructed facilities are becoming less expensive, and more practical, for small and large drug manufacturers alike.
A talk with Hydes Peter Watler about trends shaping biopharma facilities today and tomorrow.
MedImmunes approach may help take the blame off automation for plant startup delays.
When equipment and processes challenge solvent recovery for small-volume streams, an atypical approach is needed, says Pfizers Frank Urbanski.
Communities can partner with manufacturers, but they cant apply pressure.
Rapid microbiological methods continue to be developed in order to support or supplant compendial methods.
Makers of drugs for lethal injection face pressure to spurn U.S. prisons.
Probabilistic rather than deterministic modeling is essential, says Quintiles Davis Walp.
Middle managers in pharma today have a tough, thankless jobbut someones got to do it, and many do it well.